XenoSTART

Biotechnology Research • San Antonio, Texas, United States • 21-50 Employees

Company overview

Headquarters	San Antonio, Texas, United States
Website	xenostart.com
NAICS	541714
Employees	21-50
Socials

Key Contacts at XenoSTART

Michael Wick

Cso, Director Of Research

Christopher Brenzel

Director Of Business Development

Alyssa Simonson

Director Of Operations

Jim Lund

Director Of Bioinformatics

XenoSTART Email Formats

XenoSTART uses 2 email formats. The most common is {first name}.{last name} (e.g., john.doe@xenostart.com), used 72% of the time.

Format	Example	Percentage
{first name}.{last name}	john.doe@xenostart.com	72%
{first initial}.{last name}	j.doe@xenostart.com	28%

About XenoSTART

XenoSTART is an industry-leading oncology translational research organization focused on the development and utilization of PDX models. Founded in 2007, XenoSTART was created in close collaboration with The START Center, an international cancer treatment and research organization. This partnership provides the unique ability to generate clinically-relevant XenoSTART patient-derived xenograft (XPDX) models. Our diverse repository of XPDX (XenoSTART PDX) models are clinically annotated and include patient treatment history and outcome. The models are characterized through genomic profiling, histologic analysis, next generation sequencing, and in vivo drug sensitivity to relevant standards of care. Our models can accelerate preclinical discovery and drug development through the following turn-key services: In vivo PK/PD and efficacy studies In-licensing of models for proprietary studies Orthotopic and radiotherapy studies [collaboration with our partners] Ex vivo and organoid studies [collaboration with our partners] In vivo efficacy panel screens [indication or target focused] Cell line development Custom model development

XenoSTART revenue & valuation

Annual revenue	$2,224,430
Revenue per employee	$86,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$7,200,000
Total funding	No funding